Catégorie : Essais Cliniques

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis, Sara Arias et al., 2021

Clinical Evidence of Magistral Preparations Based on Medicinal Cannabis Sara Arias, Marta Leon, Diego Jaimes and Rosa-Helena Bustos Pharmaceuticals, 2021, 14, 78, 1-13. Doi :10.3390/ph14020078   Abstract : Cannabis has been widely used as a medicinal plant for millennia; however, studies related to its main components were first conducted in 1960. Subsequently, laboratories have produced new components and structures related to its active biological properties. Countries that have approved the medicinal use of cannabis impose regulations that govern its clinical and scientific use. One means of administering medicinal cannabis is via a magistral preparation that must have a medical prescription and be prepared in an establishment [...]

Lire la suite

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain, Marta Vázquez et al., 2020,

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain Marta Vázquez, Natalia Guevara, Cecilia Maldonado, Paulo Cáceres Guido, and Paula Schaiquevich Hindawi, BioMed Research International, 2020, Article ID 3902740, 9 pages Doi : 10.1155/2020/3902740 Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

The Impact of Cannabidiol on Psychiatric and Medical Conditions, Thersilla Oberbarnscheidt & Norman S. Miller, 2019

The Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159   Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]

Lire la suite

Cannabis for Migraine Strongly Linked to Rebound Headache, Megan Brooks, Medscape Medical News, 2021

Cannabis for Migraine Strongly Linked to Rebound Headache Megan Brooks Medscape Medical News © March 09, 2021 Patients with chronic migraine who turn to cannabis to relieve headache pain may be setting themselves up for medication overuse headache, preliminary research suggests, although the direction of the relationship is unclear. Researchers at Stanford University School of Medicine, Stanford, California, found a significant increase in the likelihood of medication overuse headache (rebound headache) in chronic migraine patients who use cannabis. Dr Niushen Zhang "This study shows that there is some kind of association between cannabis use and medication overuse headache in people with chronic migraine," lead investigator Niushen Zhang, MD, [...]

Lire la suite

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence, Mélissa Prud’homme et al., 2015

Cannabidiol as an Intervention for Addictive Behaviors : A Systematic Review of the Evidence Mélissa Prud’homme, Romulus Cata and Didier Jutras-Aswad Substance Abuse : Research and Treatment,  2015, 9, 33-38. doi : 10.4137/SART.S25081.   Abstract : Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of cannabis, is thought to modulate various neuronal circuits involved in drug addiction. The goal of this systematic review is to summarize the available preclinical and clinical data on the impact of CBD on addictive behaviors. MEDLINE and PubMed were searched [...]

Lire la suite

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD, Deborah Brauser, Medscape.com, 2021

Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print   Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]

Lire la suite

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca, Nicole Leite Galvão-Coelho et al., 2020

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca Nicole Leite Galvão-Coelho, Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Fernanda Palhano-Fontes, Isaac Campos Braga, Bruno Lobão Soares, João Paulo Maia-de-Oliveira, Daniel Perkins, Jerome Sarris and Draulio Barros de Araujo Journal of Psychopharmacology, 2020, 1-9. DOI : 10.1177/0269881120936486   Abstract Background : Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). Aims : We are evaluating the blood inflammatory biomarkers: C-reactive protein and [...]

Lire la suite

Neuroprotection Following Concussion : The Potential Role for Cannabidiol, Jyotpal Singh, John Patrick Neary, 2020

Neuroprotection Following Concussion : The Potential Role for Cannabidiol Jyotpal Singh, John Patrick Neary Canadian Journal of Neurological Sciences, 2020,  1–12 doi : 10.1017/cjn.2020.23   ABSTRACT : Cannabidiol (CBD) has been generating increasing interest in medicine due to its therapeutic properties and an apparent lack of negative side effects. Research has suggested that high dosages of CBD can be taken acutely and chronically with little to no risk. This review focuses on the neuroprotective effects of a CBD, with an emphasis on its implications for recovering from a mild traumatic brain injury (TBI) or concussion. CBD has been shown to influence the endocannabinoid system, both by [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite